Cogent Biosciences (COGT) Payables (2017 - 2026)

Cogent Biosciences (COGT) has reported Payables for 10 consecutive years, with $13.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Payables fell 2.9% year-over-year to $13.7 million; the TTM figure through Mar 2026 stood at $13.7 million (down 2.9% YoY), while the FY2025 annual figure was $9.5 million, down 20.89% from the prior year.
• Payables improved to $13.7 million in Q1 2026 per COGT's latest filing, from $9.5 million in the prior quarter.
• Across five years, Payables topped out at $16.6 million in Q2 2025 and bottomed at $3.5 million in Q2 2022.
• Historically, Payables has averaged $10.1 million across 5 years, with a median of $9.9 million in 2023.
• Annual changes were most pronounced in 2022 — Payables surged 1174.6% — and 2025, when it retreated 20.89%.
• Cogent Biosciences' Payables stood at $5.8 million in 2022, then soared by 82.39% to $10.7 million in 2023, then gained by 12.75% to $12.0 million in 2024, then declined by 20.89% to $9.5 million in 2025, then soared by 44.61% to $13.7 million in 2026.
• Business Quant data shows COGT's Payables at $13.7 million in Q1 2026, $9.5 million in Q4 2025, and $16.0 million in Q3 2025.